FDA Approves Novartis’s Cosentyx for Polymyalgia Rheumatica, First Biologic of Its Kind for the Condition

Novartis building in Basel, Switzerland Photo: Silesia711 / Wikimedia Commons (CC BY-SA 4.0)

The US Food and Drug Administration has approved Novartis’s drug Cosentyx for adults with polymyalgia rheumatica, making it the first biologic of its kind cleared for the condition and giving patients a new option beyond long-term steroid treatment.

Novartis announced the approval on Tuesday. Cosentyx, known generically as secukinumab, is approved at a 150 mg dose for adults whose disease has not responded adequately to corticosteroids, or who cannot tolerate tapering off them. It is the first and only drug that blocks interleukin-17, a protein involved in inflammation, to be approved for polymyalgia rheumatica.

Polymyalgia rheumatica is a common inflammatory disease that mainly affects people over 50, causing pain and stiffness in the shoulders, neck and hips. For decades the standard treatment has been long-term corticosteroids, which can bring serious side effects when used for months or years, including weight gain, diabetes, bone loss and raised blood pressure.

The approval rests on the REPLENISH trial, a global Phase III study run in 27 countries that compared Cosentyx with a placebo in patients tapering off steroids. After 52 weeks, 40.5 per cent of patients on Cosentyx were in sustained remission, double the 20.5 per cent on placebo, and the drug showed steroid-sparing effects. The results were published in the New England Journal of Medicine and presented at the European rheumatology congress in June.

The decision is the eleventh US indication for Cosentyx, a fully human biologic that inhibits interleukin-17A and is already used for psoriasis, psoriatic arthritis, ankylosing spondylitis and other inflammatory conditions. Novartis said the polymyalgia rheumatica indication is already approved in the European Union, with reviews still under way in Japan and other countries.

The approval is based on a single pivotal trial, and Novartis has not published a price for the new indication.

Sources: Novartis — “Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)” (https://www.tradingview.com/news/globenewswire:e534ef9da094b:0-novartis-cosentyx-becomes-first-and-only-fda-approved-anti-il-17-biologic-for-people-with-polymyalgia-rheumatica-pmr/)

Leave a Reply

Your email address will not be published. Required fields are marked *